Ziprasidone (Geodon)
Second generation antipsychotic (dopamine, serotonin receptor antagonist (D2, 5-HT2))
- Schizophrenia3
- Treatment resistant depression3
- Deepens sleep quality
- Mania/mixed3
- Low metabolic risks
Features
Dosing
In schizophrenia and mania, Start 40 mg bid and raise to target (60-80 mg bid) by day 3. You can also give all at night, but must take with full meal (500 kcal). Surprisingly, ziprasidone is better tolerated when titrated quickly.
Absorption drops 50% if taken on an empty stomach.
INTERACTIONS: Raise by 1.5-2x if using with carbamazepine. Lower with strong CYP2D6 inhibitors (bupropion, duloxetine, fluoxetine, paroxetine, sertraline ≥150 mg/day, tricyclics, cannabidiol, clozapine, risperidone, asenapine, some first-generation antipsychotics).
Management
Some side effects improve at higher doses (>120 mg/d).
TOLERABILITY: Sedation, GI distress, EPS (dystonia, stiffness), anticholinergic.
RISKS: Tardive dyskinesia (25% over 10 years, higher in elderly), prolactinemia (can lead to breast cancer, osteopenia, sexual dysfunction), orthostasis (falls), QTc prolongation, temperature imbalance in elderly, NMS (muscle rigidity, fever, tachycardia).
Largely free of metabolic risks and akathisia.
EMR Text
Bipolar
Ziprasidone use based on FDA approval in bipolar disorder.
Antipsychotic side effects, including metabolic, prolactinemia, and TD, reviewed with patient.
Depression
Ziprasidone use based on a controlled trial for antidepressant augmentation, where it improved depressive, anxious, and mixed symptoms (Papakostas GI, Am J Psychiatry. 2015;172(12):1251-1258).
Antipsychotic side effects, including metabolic, prolactinemia, and TD, reviewed with patient.
Schizophrenia
Ziprasidone use based on FDA approval in schizophrenia.
Antipsychotic side effects, including metabolic, prolactinemia, and TD, reviewed with patient.